Haemonetics CORP

Haemonetics Corporation has entered into a non-exclusive supply agreement with CSL Plasma Inc. for its NexSys PCS devices and Persona PLUS technology, with an update on fiscal 2027 impact expected in November 2026.

Haemonetics Corporation reported a robust first quarter for fiscal year 2027, exceeding expectations with a 5.6% revenue increase and raising its full-year guidance.

Haemonetics Corporation announced the election of Martin Madaus to its Board of Directors and shareholder approval of amendments to its Long-Term Incentive Compensation Plan and Employee Stock Purchase Plan.

Haemonetics Corporation is consolidating its reportable segments into Apheresis and MedSurg to better align with its internal management structure.

Haemonetics Corporation announced fourth quarter and fiscal year 2026 financial results, highlighting revenue growth and providing fiscal 2027 guidance.

Long-serving director Charles J. Dockendorff has announced he will not seek re-election at the upcoming 2026 Annual Meeting of Shareholders.

Haemonetics Corporation announced its first quarter fiscal year 2027 results, showcasing a 5.6% increase in net revenues to $339.4 million and a 6.7% rise in operating income, driven by strong performance in its Apheresis and MedSurg segments.

Haemonetics Corporation reported a 19.3% increase in net income for the third quarter of fiscal 2026, reaching $44.7 million, despite a 2.7% decline in net revenues to $339.0 million, and completed the acquisition of Vivasure Medical Limited.

Haemonetics Corporation reported increased net income and diluted EPS for Q2 FY26, driven by improved gross profit and operating income despite a revenue decline from planned divestitures and customer transitions.

Haemonetics Corporation reported a 35.5% surge in operating income and a significant improvement in cash flow from operations for Q1 FY26, despite a 4.4% decline in net revenues driven by planned divestitures and customer transitions.

Haemonetics Corporation announces its Q3 2025 financial results, highlighting revenue growth driven by the Hospital segment, while Plasma and Blood Center segments face declines.

Haemonetics Corporation's second quarter of fiscal year 2025 shows revenue growth driven by the Hospital segment, but mixed results in profitability and increased operating expenses.

Haemonetics Corporation's fiscal year 2026 annual report details a 2.0% decrease in net revenues to $1.33 billion, impacted by portfolio transitions, while the Hospital segment showed growth.

Haemonetics Corporation's fiscal 2025 results show a 4.0% increase in net revenues, driven primarily by growth in the Hospital segment, while Plasma and Blood Center segments experienced declines.

Haemonetics' fiscal year 2024 shows revenue growth driven by Plasma and Hospital segments, alongside strategic initiatives to manage costs and expand in key markets.

Martin D Madaus, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.

Ellen M Zane, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.

Claire Pomeroy, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.

Mark W Kroll, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.

Lloyd Emerson Johnson, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.

Michael J Coyle, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.

Haemonetics Corporation announced its 2026 Annual Meeting of Shareholders will be held on July 24, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Haemonetics Corporation has filed definitive additional proxy materials with the SEC, indicating further disclosures related to its upcoming shareholder meeting.

Haemonetics Corporation announces its 2025 Annual Meeting of Shareholders to be held on July 24, 2025, with proposals including the election of directors, executive compensation, and ratification of the accounting firm.

Haemonetics Corporation has filed a definitive proxy statement with the SEC.

Haemonetics Corporation has released its proxy statement outlining the agenda for its 2024 Annual Meeting of Shareholders, including the election of directors, executive compensation, and ratification of the independent auditor.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Haemonetics Corp. common stock.

North Peak Capital Management and affiliated entities have filed an amendment to their Schedule 13G, reporting 0% beneficial ownership of Haemonetics Corp. common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.26% of Haemonetics Corp. common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.59% of Haemonetics Corp's common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Haemonetics Corp following an internal realignment that disaggregated reporting responsibilities.

North Peak Capital Management, LLC and affiliated entities have reported a 5.1% beneficial ownership stake in Haemonetics Corporation, totaling 2,370,495 shares.